Consensus Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-15 pm EDT			5-day change	1st Jan Change
36.51 ^USD	+0.75%		+2.82%	+43.12%

Jun. 30	Royalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Value-Defensive Index	CI
Jun. 30	Royalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Defensive Index	CI

Evolution of the Average Target: Royalty Pharma plc

Evolution of the Target Price: Royalty Pharma plc

Changes in Analyst Recommendations: Royalty Pharma plc

ca24a2bb679091d3.TwMS2jZCm-zZG9huvpmj8oxHLgjTGpEu_fgySYWUPaM.HTNYi2d184WjI48lzP3WuvoFRVmgfOh5uM8He9DcBeJ-VlS1AAatqao2jQ~8790b207a30aed951b07580615bddf21

Analysts' recommendations: Royalty Pharma plc

BofA Adjusts Price Target on Royalty Pharma to $42 From $41	Apr. 21	MT
Analyst recommendations: Cheniere, Gilead, Lowe's, Palo Alto, Starbucks...	24-08-21
Goldman Sachs Adjusts Royalty Pharma Price Target to $51 From $50, Maintains Buy Rating	24-08-14	MT
Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	24-04-09	MT
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating	24-02-20	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating	24-02-20	MT
Morgan Stanley Cuts Price Target on Royalty Pharma to $46 From $57, Keeps Overweight Rating	23-12-12	MT
Analyst recommendations: Adobe, Amgen, Blackrock, IBM, Ulta Beauty...	23-12-12
Morgan Stanley Adjusts Price Target on Royalty Pharma to $57 From $54, Maintains Overweight Rating	23-11-09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $54 From $53, Maintains Overweight Rating	23-10-11	MT
UBS Adjusts Royalty Pharma Price Target to $41 From $44, Maintains Buy Rating	23-08-09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $53 From $52, Maintains Overweight Rating	23-08-09	MT
UBS Adjusts Royalty Pharma Price Target to $44 From $48, Maintains Buy Rating	23-07-24	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $52 From $50, Maintains Overweight Rating	23-05-10	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $50 From $48, Maintains Overweight Rating	23-04-10	MT
UBS Adjusts Royalty Pharma's Price Target to $48 From $51, Maintains Buy Rating	23-02-16	MT
Morgan Stanley Cuts Price Target on Royalty Pharma to $51 From $54, Maintains Overweight Rating	22-12-06	MT
UBS Adjusts Royalty Pharma Price Target to $51 From $50, Maintains Buy Rating	22-11-09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $54 From $51, Maintains Overweight Rating	22-11-09	MT
JPMorgan Chase Adjusts Royalty Pharma's Price Target to $52 From $50, Keeps Overweight Rating	22-10-18	MT
Morgan Stanley Increases Royalty Pharma's Price Target to $51 From $48, Maintains Overweight Rating	22-08-08	MT
Goldman Sachs Adjusts Price Target for Royalty Pharma to $56 From $55, Maintains Buy Rating	22-08-05	MT
Citigroup Adjusts Price Target on Royalty Pharma to $60 From $50, Reiterates Buy Rating	22-07-29	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $55 From $57, Maintains Buy Rating	22-07-28	MT
Tigress Financial Adjusts Royalty Pharma's Price Target to $57 From $52, Maintains Buy Rating	22-07-14	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Ecart obj. / dr
ROYALTY PHARMA PLC		+15.61%
ELI LILLY AND COMPANY		+19.13%
JOHNSON & JOHNSON		+7.86%
ABBVIE INC.		+9.19%
NOVO NORDISK A/S		+45.46%
ROCHE HOLDING AG		+16.95%
NOVARTIS AG	-	+0.21%
ASTRAZENECA PLC		+28.47%
MERCK & CO., INC.		+21.65%
AMGEN INC.		+5.56%
Average		+17.01%
Weighted average by Cap.		+17.67%